© BOWDEN IMAGES/ ISTOCKPHOTO.COM MODELS USED FOR ILLUSTRATIVE PURPOSES ONLY
1. Van Buynder P. Enhancing influenza vaccination in older people. Med Today 2019; 20(2 Suppl): 6-10.
2. Van Buynder P. Reducing pneumococcal risk in people aged 65 years and over. Med Today 2019; 20(2 Suppl): 11-14.
3. Litt JCB, Cunningham AL. Herpes zoster: improving protection in older people. Med Today 2019; 20(2 Suppl): 16-22.
4. McIntyre P, Amin J, Gidding H, et al. Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998. Commun Dis Intell 2000: Suppl; v83.
5. Quinn HE, McIntyre PB. Tetanus in the elderly - an important preventable disease in Australia. Vaccine 2007; 25: 1304-1309.
6. Richardson JP, Knight AL. The prevention of tetanus in the elderly. Arch Intern Med 1991; 151: 1712-1717.
7. Borella-Venturini M, Frasson C, Paluan F, et al. Tetanus vaccination, antibody persistence and decennial booster: a serosurvey of university students and at-risk workers. Epidemiol Infect 2017; 145: 1757-1762.
8. Lee HJ, Choi JH. Tetanus-diphtheria-acellular pertussis vaccination for adults: an update. Clin Exp Vaccine Res 2017; 6: 22-30.
9. Australian Technical Advisory Group on Immunisation (ATAGI). Australian immunisation handbook. Canberra: Australian Government Department of Health; 2018. Available online at: https://immunisationhandbook.health.gov.au (accessed February 2019).
10. Ridda I, Yin JK, King C, Raina MacIntyre C, McIntyre P. The importance of pertussis in older adults: a growing case for reviewing vaccination strategy in the elderly. Vaccine 2012; 30: 6745-6752.
11. National Centre for Immunisation Research and Surveillance (NCIRS). Immunisation recommendations for adults in Australia. Sydney: NCIRS; 2018. Available online at: https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/immunisation-for-adults (accessed February 2019).
12. Grondahl-Yli-Hannuksela K, Kauko L, Van Der Meeren O, Mertsola J, He Q. Pertussis specific cell-mediated immune responses ten years after acellular pertussis booster vaccination in young adults. Vaccine 2016; 34: 341-349.
13. van der Lee S, van Rooijen DM, de Zeeuw-Brouwer ML, et al. Robust humoral and cellular immune responses to pertussis in adults after a first acellular booster vaccination. Front Immunol 2018; 9: 681.
14. Veitch MG, Owen RL. Rise in invasive serogroup W meningococcal disease in Australia 2013-2015. Commun Dis Intell Q Rep 2016; 40: E451-E453.
15. Booy R, Gentile A, Nissen M, Whelan J, Abitbol V. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum Vaccin Immunother 2018; 1-11. doi: 10.1080/21645515.2018.1532248 [Epub ahead of print].
16. National Centre for Immunisation Research and Surveillance (NCIRS). Meningococcal vaccines: frequently asked questions. Sydney: NCIRS; 2019. Available online at: http://ncirs.org.au/ncirs-fact-sheets-faqs/hpv-vaccines-faqs (accessed February 2019).
17. Victoria State Government Department of Health and Human Services. Outbreak of invasive meningococcal C disease in men who have sex with men (MSM). Health alert 7 December 2017. Available online at: www2.health.vic.gov.au/about/news-and-events/healthalerts/alert-meningococcal-c-december-2017 (accessed February 2019).
18. National Centre for Immunisation Research and Surveillance (NCIRS). Haemophilus influenzae type b (Hib) vaccines for Australian children. NCIRS Fact sheet. Sydney: NCIRS; 2018. Available online at: www.ncirs.org.au/ncirs-fact-sheets-faqs/haemophilus-influenzae-type-b-hib-vaccines-australian-children (accessed February 2019).
19. Australian Technical Advisory Group on Immunisation (ATAGI). Vaccination for people who are immunocompromised. Canberra: Australian Government Department of Health; 2018. Available online at: https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-people-who-are-immunocompromised (accessed February 2019).
20. Spleen Australia, Alfred Hospital. Recommendations for the prevention of infection in asplenic (splenectomy) or hyposplenic patients over 18 years of age (V35 Jan 2019). Melbourne: Alfred Hospital. Available online at: https://spleen.org.au/VSR/files/RECOMMENDATIONS_Spleen_Registry.pdf (accessed February 2019).
21. Australian Technical Advisory Group on Immunisation (ATAGI). Vaccination for international travellers. Canberra: Australian Government Department of Health; 2018. Available online at: https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-international-travellers (accessed February 2019).
22. Seale H, Macintyre CR. Seasonal influenza vaccination in Australian hospital health care workers: a review. Med J Aust 2011; 195: 336-338.
23. Ward K, Seale H, Zwar N, Leask J, Macintyre CR. Annual influenza vaccination: coverage and attitudes of primary care staff in Australia. Influenza Other Respir Viruses 2011; 5: 135-141.
24. Weltevrede M, Eilers R, de Melker HE, van Baarle D. Cytomegalovirus persistence and T-cell immunosenescence in people aged fifty and older: a systematic review. Exp Gerontol 2016; 77: 87-95.
25. Aiello AE, Chiu YL, Frasca D. How does cytomegalovirus factor into diseases of aging and vaccine responses, and by what mechanisms? Geroscience 2017; 39: 261-271.
26. McElhaney JE, Zhou X, Talbot HK, et al. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine 2012; 30: 2060-2067.
27. Goodier MR, Jonjic S, Riley EM, Juranic Lisnic V. CMV and natural killer cells: shaping the response to vaccination. Eur J Immunol 2018; 48: 50-65.
28. John S, Yuzhakov O, Woods A, et al. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine 2018; 36: 1689-1699.
29. Plotkin SA, Boppana SB. Vaccination against the human cytomegalovirus. Vaccine 2018; pii: S0264-410X(18)30288-3.
30. Falsey AR, McElhaney JE, Beran J, et al. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis 2014; 209: 1873-1881.
31 Haber N. Respiratory syncytial virus infection in elderly adults. Med Mal Infect 2018; 48: 377-382.
32. Roberts JN, Graham BS, Karron RA, et al. Challenges and opportunities in RSV vaccine development: meeting report from FDA/NIH workshop. Vaccine 2016; 34: 4843-4849.
33. Boivin G, De Serres G, Hamelin ME, et al. An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin Infect Dis 2007; 44: 1152-1158.
34. Marquez-Escobar VA. Current developments and prospects on human metapneumovirus vaccines. Expert Rev Vaccines 2017; 16: 419-431.
35. Ren J, Phan T, Bao X. Recent vaccine development for human metapneumovirus. J Gen Virol 2015; 96(Pt 7): 1515-1520.
36. Braczynski AK, Schulz JB, Bach JP. Vaccination strategies in tauopathies and synucleinopathies. J Neurochem 2017; 143: 467-488.
COMPETING INTERESTS: Associate Professor Woodward has received funds for sitting on advisory boards and participating in educational events for Seqirus, Sanofi, MSD and GlaxoSmithKline. Associate Professor Litt has received funds for sitting on advisory boards for Seqirus and GlaxoSmithKline and speaker’s fees from Seqirus when providing educational updates on zoster vaccination for a range of healthcare providers.